Study Objective Despite evidence that supports the use of sacubitril/valsartan–the first
angiotensin II receptor blocker–neprilysin inhibitor–for mortality reduction in patients with …

Background Heart failure (HF) is a growing public health problem. Sacubitril/valsartan is
now recommended to be used in persistently symptomatic patients with left ventricular …

Introduction: Sacubitril-valsartan is a combination drug that contains the neprilysin inhibitor
sacubitril and angiotensin II receptor blocker valsartan. In 2015, the US Food and Drug …

The new Universal Definitionfor Heart Failure partitions heart failure phenotypes according
to ejection fraction criteria. 1 For those with signs and symptoms of heart failure and a …

Background Sacubitril‐valsartan, an inhibitor of the angiotensin receptor neprilysin (ARNi),
has been purported to exhibit superiority over angiotensin converting enzyme (ACE) …

Aims To analyse real‐world treatment patterns of sacubitril/valsartan (sac/val) using data
from a pharmacy database in Germany. Methods and results A retrospective cohort study of …

Heart failure (HF) is one of the leading causes of morbidity and mortality worldwide.
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has been approved for the …

Background: In the Prospective Comparison of angiotensin receptor neprilysin inhibitor
(ARNI) With ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure …

Introduction Hypertension is a significant risk factor in heart failure for worldwide patients.
More than half of hypertensive patients suffer from heart failure. Recently, sacubitril/valsartan …

The use of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers
(ARBs), beta-blockers and mineralocorticoid receptor antagonists (MRAs) has led to …